potential COVID-19 treatments - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.94 [0.88, 1.00]< 122%54 studies (54/-)97.7 %some concerncritical moderatecrucial-
death or transfer to ICU 0.88 [0.64, 1.23]< 146%4 studies (4/-)76.7 %some concernnot evaluable moderatecrucial-
deaths 0.93 [0.90, 0.97]< 115%124 studies (124/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.89 [0.80, 0.99]< 145%24 studies (24/-)98.6 %some concerncritical moderatecrucial-
clinical deterioration 0.74 [0.62, 0.89]< 146%29 studies (29/-)99.9 %some concernlow moderateimportant-
clinical improvement 1.18 [1.08, 1.28]> 142%41 studies (41/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.17 [0.99, 1.37]> 145%22 studies (22/-)97.0 %some concernlow moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.24 [1.08, 1.41]> 141%18 studies (18/-)99.9 %some concerncritical moderateimportant-
clinical improvement (7-day) 1.23 [1.02, 1.48]> 156%16 studies (16/-)98.5 %some concerncritical moderateimportant-
clinical improvement (time to event analysis only) 1.19 [1.11, 1.27]> 117%25 studies (25/-)100.0 %some concerncritical moderateimportant-
death or ventilation